论文部分内容阅读
目的 :对 32例造血干细胞移植 (AHSCT)治疗恶性血液病和实体瘤的有关资料进行总结分析。方法 :ABMT组 16例 (NHL 7例 ,HL 6例 ,AML 2例 ,AL L 1例 ) ,13例采用 CBVA方案预处理 ,2例采用 HD- CTX+ TL I,1例采用 TBI+ HD- CTX预处理。APBSCT组 16例 (NHL 11例 ,HL 3例 ,MM1例 ,SCL C1例 )用 CTX+G- CSF+ DXM方案动员 ,NHL 采用 CBV方案预处理 ,MM采用 CBM处理 ,SCL C采用 CEP方案处理。结果 :ABMT组 3年、5年生存率在 NHL组为 75 %、75 % ,HL组分别为 10 0 %、83.3 % ;APBSCT组 NHL的 2年、3年生存率为 80 .6 %、6 8.7% ,HL 的 2年、3年生存率均为 10 0 %。 1例 MM、2例 AML、1例 AL L 和 SCL C的存活期分别为 5年、19月、2年和 14月。移植相关死亡率为 0。结论 :造血干细胞移植是治疗恶性血液疾病及实体瘤 ,改善预后的主要手段之一。 ABMT组与 APBSCT组疗效相近 ,患者造血恢复快 ,严重感染发生率低。
Objective : To summarize and analyze the data of 32 cases of hematopoietic stem cell transplantation (AHSCT) in the treatment of hematological malignancies and solid tumors. Methods: 16 cases in ABMT group (7 cases in NHL, 6 cases in HL, 2 cases in AML, 1 case in AL L), 13 cases were pretreated with CBVA regimen, 2 cases were treated with HD-CTX + TL I, 1 case was pre-treated with TBI + HD-CTX deal with. Sixteen patients in the APBSCT group (11 in the NHL, 3 in the HL, 1 in the MM, and 1 in the SCL) were mobilized using the CTX+G-CSF+DXM protocol. The NHL was pretreated with the CBV protocol, the MM was treated with the CBM, and the SCL C was treated with the CEP protocol. Results: The three-year and five-year survival rates in ABMT group were 75% and 75% in NHL group and 100% and 83.3% in HL group respectively. The 2-year and 3-year survival rate of NHL in APBSCT group was 80.6 %. At 8.7%, the 2-year and 3-year survival rates for HL were all 10%. The survival times of 1 case of MM, 2 cases of AML, 1 case of AL L and SCL C were 5 years, 19 months, 2 years and 14 months respectively. Transplant-related mortality is 0. Conclusion: Hematopoietic stem cell transplantation is one of the main methods to treat malignant hematological diseases and solid tumors and improve their prognosis. The ABMT group and APBSCT group had similar efficacy. Hematopoietic recovery was rapid and the incidence of severe infection was low.